Merck's Q2 Sales Got Clobbered by COVID-19, but Still Beat Estimates
So far, 2020 has not turned out like Merck (NYSE: MRK) hoped it would: The big drugmaker's blockbuster oncology treatment Keytruda flopped in late-stage studies targeting bladder cancer and small-cell lung cancer. As a result of these setbacks, as well as the COVID-19 pandemic, Merck's shares declined, and remained down more than 10% year to date as of the market close on Thursday.
However, shareholders could now have reason to smile again, based on the second-quarter results Merck released before the market opened on Friday. Here are the highlights from that update.
Image Source: Getty Images.
Source Fool.com
